Increased risk and severity of unprovoked venous thromboembolism with clustering cardiovascular risk factors for atherosclerosis: Results of the REMOTEV registry.

[1]  P. Prandoni,et al.  An association between residual vein thrombosis and subclinical atherosclerosis: Cross-sectional study. , 2017, Thrombosis research.

[2]  U. Demkow,et al.  E-selectin and sICAM-1, biomarkers of endothelial function, predict recurrence of venous thromboembolism. , 2017, Thrombosis research.

[3]  J. Manson,et al.  Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism: An Individual Participant Data Meta-Analysis of Prospective Studies. , 2017, Circulation.

[4]  W. Ageno,et al.  Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH , 2016, Journal of thrombosis and haemostasis : JTH.

[5]  E. Cordeanu,et al.  Statins and prevention of venous thromboembolism: Myth or reality? , 2016, Archives of cardiovascular diseases.

[6]  G. Suddek,et al.  Attenuation of oxidative stress, inflammation, and endothelial dysfunction in hypercholesterolemic rabbits by allicin. , 2016, Canadian journal of physiology and pharmacology.

[7]  M. Prins,et al.  The Impact of Residual Thrombosis on the Long-Term Outcome of Patients with Deep Venous Thrombosis Treated with Conventional Anticoagulation , 2015, Seminars in Thrombosis & Hemostasis.

[8]  Jose Luis Zamorano,et al.  The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC) Endorsed by the European Respiratory Society (ERS) , 2014 .

[9]  P. Prandoni,et al.  Further evidence in support of the association between venous thrombosis and atherosclerosis: a case-control study. , 2014, Thrombosis research.

[10]  D. S. Fuentes,et al.  Enfermedad tromboembólica venosa idiopática versus secundaria , 2014 .

[11]  M. Monreal,et al.  Enfermedad tromboembólica venosa idiopática versus secundaria. Hallazgos del registro RIETE , 2014 .

[12]  M. Monreal,et al.  Idiopathic versus secondary venous thromboembolism. Findings of the RIETE registry. , 2014, Revista clinica espanola.

[13]  T. Lüscher,et al.  Dual Role of Endothelial Nitric Oxide Synthase in Oxidized LDL-Induced, p66Shc-Mediated Oxidative Stress in Cultured Human Endothelial Cells , 2014, PloS one.

[14]  P. Prandoni,et al.  Aspirin for the Prevention of Recurrent Venous Thromboembolism: The INSPIRE Collaboration , 2014, Circulation.

[15]  S. Suissa,et al.  Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. , 2013, The American journal of medicine.

[16]  M. Gianni,et al.  The role of the metabolic syndrome in patients with provoked venous thromboembolic events , 2013, Thrombosis and Haemostasis.

[17]  D. Xavier,et al.  Low-dose aspirin for preventing recurrent venous thromboembolism. , 2012, The New England journal of medicine.

[18]  W. Ageno,et al.  Aspirin for preventing the recurrence of venous thromboembolism. , 2012, The New England journal of medicine.

[19]  Elie A Akl,et al.  Antithrombotic Therapy for VTE Disease: CHEST Guideline and Expert Panel Report. , 2012, Chest.

[20]  Paolo Prandoni,et al.  Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. , 2012, Chest.

[21]  P. Scarabin,et al.  Risk assessment for recurrent venous thrombosis , 2011, The Lancet.

[22]  G. Jensen,et al.  Risk Factors for Venous Thromboembolism: Results From the Copenhagen City Heart Study , 2010, Circulation.

[23]  L. Lusa,et al.  Idiopathic venous thrombosis is associated with preclinical atherosclerosis. , 2010, Journal of atherosclerosis and thrombosis.

[24]  Yang-ming Yang,et al.  eNOS uncoupling and endothelial dysfunction in aged vessels. , 2009, American journal of physiology. Heart and circulatory physiology.

[25]  L. Rodríguez-Mañas,et al.  Endothelial dysfunction in aged humans is related with oxidative stress and vascular inflammation , 2009, Aging cell.

[26]  P. Libby,et al.  Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.

[27]  Piotr Pruszczyk,et al.  Guidelines on the Diagnosis and Management of Acute Pulmonary Embolism , 2008 .

[28]  P. Vanhoutte,et al.  Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. , 2008, Physiological genomics.

[29]  P. Poredos,et al.  The role of inflammation in venous thromboembolism and the link between arterial and venous thrombosis. , 2007, International angiology : a journal of the International Union of Angiology.

[30]  Cecilia Becattini,et al.  Cardiovascular Risk Factors and Venous Thromboembolism: A Meta-Analysis , 2008, Circulation.

[31]  A. Folsom,et al.  Prospective study of subclinical atherosclerosis as a risk factor for venous thromboembolism , 2006, Journal of thrombosis and haemostasis : JTH.

[32]  A. Folsom,et al.  Subclinical atherosclerosis and the risk of future venous thrombosis in the Cardiovascular Health Study , 2006, Journal of thrombosis and haemostasis : JTH.

[33]  M. Björck,et al.  Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23 796 consecutive autopsies , 2006, Journal of thrombosis and haemostasis : JTH.

[34]  W. Ageno,et al.  The metabolic syndrome and the risk of venous thrombosis: a case–control study , 2006, Journal of thrombosis and haemostasis : JTH.

[35]  P. Prandoni,et al.  Incidence of arterial cardiovascular events in patients with idiopathic venous thromboembolism , 2006, Thrombosis and Haemostasis.

[36]  W. Ageno,et al.  A prospective study on cardiovascular events after acute pulmonary embolism. , 2005, European heart journal.

[37]  T. Baglin,et al.  Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study , 2003, The Lancet.

[38]  John A. Heit,et al.  The epidemiology of venous thromboembolism , 2003, Journal of Thrombosis and Thrombolysis.

[39]  M. Prins,et al.  An association between atherosclerosis and venous thrombosis. , 2003, The New England journal of medicine.

[40]  J. van de Voorde,et al.  Endothelial dysfunction in diabetes , 2000, British journal of pharmacology.

[41]  E. Oger.  Incidence of Venous Thromboembolism: A Community-based Study in Western France , 2000, Thrombosis and Haemostasis.

[42]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[43]  P. Ohlmann,et al.  Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes. , 2017, International journal of cardiology.

[44]  Jeroen J. Bax,et al.  ESC Guidelines on the diagnosis and management of acute pulmonary embolism , 2014 .

[45]  Y. Long,et al.  Adiponectin directly improves endothelial dysfunction in obese rats through the AMPK–eNOS Pathway , 2010, International Journal of Obesity.

[46]  W. Ageno,et al.  A prospective study on cardiovascular events after acute pulmonary embolism , 2005 .